Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 300 participants.
Also called NCT02738632
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 300 participants
- Sponsor
- Registry
-
NCT02738632
-
- Other papers using this trial's data
- Efficacy and Tolerability of Telmisartan/Amlodipine + Hydrochlorothiazide Versus Telmisartan/Amlodipine Combination Therapy for Essential Hypertension Uncontrolled With Telmisartan/Amlodipine: The Phase III, Multicenter, Randomized, Double-blind TAHYTI Study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT02738632. Randomized; double masking; primary purpose treatment. Start 2015-05 (registry gives no type); primary completion 2016-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients
- Condition
- Essential Hypertension
- Intervention (Drug)
- Telmisartan/Amlodipine+Hydrochlorothiazide
- Intervention (Drug)
- Telmisartan/Amlodipine
- Intervention (Drug)
- Placebo for Hydrochlorothiazide
- Lead sponsor
- IlDong Pharmaceutical Co Ltd
Record details
- Record id
cardio:ct-nct02738632- Content hash
6603a278f607b5a37f618f3a1c3669ad9fc3291a37fea4d5ad0d4ee6114a114c